Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Intellicell Biosciences announces the licensing of its proprietary patent, pending stromal vascular fraction manufacturing technology

January 11, 2012 By AxoGen, Inc.

NEW YORK–(BUSINESS
WIRE
)–Intellicell Biosciences, Inc.;
(“Intellicell”) or the (“Company”), Intellicell has licensed its proprietary,
patent, pending technology for the manufacture of stromal vascular fraction
from adipose tissue to Cell-Innovations, Pty Limited a company headquartered in
Sydney, Australia. The license calls for a one-time payment of $700,000 and a
royalty stream of 12 ½ % of net of sales.

Intellicells process is a patent-pending non-enzymatic
method for deriving stromal vascular fraction from 60ccs of adipose tissue.
This process dramatically increases the yield in manufacturing stromal vascular
fraction compared to the present enzymatic methods in use today. Intellicells
process generates between half billion – 1.4 billion SVFC cells from 60 ccs
from a patients own adipose tissue. This is approximately 10-20 times greater
than enzyme based methods. Dr. Steven Victor, CEO, said “we are extremely
excited about our licensing partnership with Cell-Innovations, Inc. We believe
they are one of the best positioned companies to market the Intellicell
technology in Australia & New Zealand.

Cell-Innovations is an Australian company headquartered in Sydney servicing the burgeoning regenerative medicine
market by providing innovative IntelliCell technology to the Australian and New Zealand
marketplace. We believe that IntelliCell technology will be a “game-changer” in
the regenerative medicine field making available stromal vascular fraction
(SVF) treatment to the public. Cell-Innovations CEO is Dr. Wayne Thomas BSc PhD
a founder of Australian Cell Technologies, a company introducing regenerative
cellular products to the veterinary market. Dr. Thomas has 25 years experience
in cell biology and developed kits for adipose SVF for the veterinary market.
Dr. Thomas research contributions has been recognized by many publications and
book chapters, and is a reviewer for both national and international granting
bodies and journals; and, will be a scientific advisor for IntelliCell. Dr
Ralph Bright MB ChB FFMACC is a director with Cell-Innovations and is a pioneer
in stromal vascular fraction treatments in Australia, a Fellow and Member of
many cosmetic medicine organizations including the Cosmetic Physicians Society of Australasia and the Australian College of Cosmetic Surgery. Dr Bright has been
treating patients with adipose SVF since 2009 for osteoarthritis and
degenerative neurological disease and is one of the most experienced physicians
in Australia
in the use of adipose SVF. “Cell-Innovations and IntelliCell will assist
Macquarie Stem Cells to establish ‘Intellicell Centers of Excellence where
doctors can treat their patient”

About IntelliCell BioSciences, Inc.

IntelliCell is a pioneering regenerative medicine company focused on the
expanding regenerative medical markets using stromal vascular fraction derived
from adult adipose tissue. IntelliCell intends to initially focus on selling
laboratory suites and licensing its technology to doctors for use in their
offices for their patients. The company is also setting upCenters of Excellence
where doctors can treat their patients. In addition, IntelliCell BioScience in
exploring storing the stromal vascular fraction in cryostorage for future uses.
The company is also starting FDA
IND clinical trials at major
medical centers for clinical indication approval. IntelliCell intends to pursue
expansion to secondary markets and beyond the U.S. through a combination of
company-owned and licensed clinical facilities. For additional information,
visit http://www.intellicellbiosciences.com or call 212-249-3050.

Posted by Sean Fenske, Editor-in-Chief, MDT

Related Articles Read More >

Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices
A Medtronic HVAD pump opened up to show the inner workings
FDA designates new Medtronic HVAD pump implant recall as Class I
Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age

DeviceTalks Weekly.

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech